Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase I Study of KAN-004 in Patients With Immune-Related Diarrhea or Colitis
NCT07196410Phase 1Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KAN-004 in immune-related colitis (IRC), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 weeks. Started Mar 2026; status: recruiting.
02
Drugs
KAN-004
03
Conditions
immune-related colitis (IRC)
Beyond the preview
Go deeper on NCT07196410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196410.